S&P 500   3,150.01 (+1.05%)
DOW   28,024.58 (+1.25%)
QQQ   204.98 (+1.26%)
AAPL   270.79 (+1.96%)
FB   200.84 (+0.74%)
MSFT   151.28 (+0.90%)
GOOGL   1,338.91 (+1.51%)
AMZN   1,751.76 (-0.51%)
NVDA   212.01 (+1.24%)
MU   47.87 (+2.68%)
BABA   201.37 (+0.69%)
GE   11.01 (+2.04%)
TSLA   337.22 (+1.26%)
T   38.31 (+0.31%)
AMD   39.65 (-0.10%)
ACB   2.42 (-0.82%)
F   9.01 (+0.90%)
PRI   136.13 (+1.36%)
NFLX   305.73 (+0.46%)
BAC   33.78 (+2.09%)
GILD   67.24 (+0.72%)
DIS   148.05 (+0.41%)
S&P 500   3,150.01 (+1.05%)
DOW   28,024.58 (+1.25%)
QQQ   204.98 (+1.26%)
AAPL   270.79 (+1.96%)
FB   200.84 (+0.74%)
MSFT   151.28 (+0.90%)
GOOGL   1,338.91 (+1.51%)
AMZN   1,751.76 (-0.51%)
NVDA   212.01 (+1.24%)
MU   47.87 (+2.68%)
BABA   201.37 (+0.69%)
GE   11.01 (+2.04%)
TSLA   337.22 (+1.26%)
T   38.31 (+0.31%)
AMD   39.65 (-0.10%)
ACB   2.42 (-0.82%)
F   9.01 (+0.90%)
PRI   136.13 (+1.36%)
NFLX   305.73 (+0.46%)
BAC   33.78 (+2.09%)
GILD   67.24 (+0.72%)
DIS   148.05 (+0.41%)
S&P 500   3,150.01 (+1.05%)
DOW   28,024.58 (+1.25%)
QQQ   204.98 (+1.26%)
AAPL   270.79 (+1.96%)
FB   200.84 (+0.74%)
MSFT   151.28 (+0.90%)
GOOGL   1,338.91 (+1.51%)
AMZN   1,751.76 (-0.51%)
NVDA   212.01 (+1.24%)
MU   47.87 (+2.68%)
BABA   201.37 (+0.69%)
GE   11.01 (+2.04%)
TSLA   337.22 (+1.26%)
T   38.31 (+0.31%)
AMD   39.65 (-0.10%)
ACB   2.42 (-0.82%)
F   9.01 (+0.90%)
PRI   136.13 (+1.36%)
NFLX   305.73 (+0.46%)
BAC   33.78 (+2.09%)
GILD   67.24 (+0.72%)
DIS   148.05 (+0.41%)
S&P 500   3,150.01 (+1.05%)
DOW   28,024.58 (+1.25%)
QQQ   204.98 (+1.26%)
AAPL   270.79 (+1.96%)
FB   200.84 (+0.74%)
MSFT   151.28 (+0.90%)
GOOGL   1,338.91 (+1.51%)
AMZN   1,751.76 (-0.51%)
NVDA   212.01 (+1.24%)
MU   47.87 (+2.68%)
BABA   201.37 (+0.69%)
GE   11.01 (+2.04%)
TSLA   337.22 (+1.26%)
T   38.31 (+0.31%)
AMD   39.65 (-0.10%)
ACB   2.42 (-0.82%)
F   9.01 (+0.90%)
PRI   136.13 (+1.36%)
NFLX   305.73 (+0.46%)
BAC   33.78 (+2.09%)
GILD   67.24 (+0.72%)
DIS   148.05 (+0.41%)
Log in

NASDAQ:HARP - Harpoon Therapeutics Stock Price, Forecast & News

$19.80
+1.84 (+10.25 %)
(As of 12/6/2019 12:50 PM ET)
Today's Range
$18.08
Now: $19.80
$21.26
50-Day Range
$12.93
MA: $14.55
$18.75
52-Week Range
$9.07
Now: $19.80
$19.99
Volume139,172 shs
Average Volume49,308 shs
Market Capitalization$487.71 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536 for the treatment of ovarian cancer and other MSLN-expressing tumors; HPN217 for the treatment of multiple myeloma; and HPN328 for the treatment of SCLC. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HARP
CUSIPN/A
CIKN/A
Phone650-443-7400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.75 million

Profitability

Net Income$-27,370,000.00
Net Margins-1,107.97%

Miscellaneous

Employees45
Market Cap$487.71 million
Next Earnings Date3/12/2020 (Estimated)
OptionableNot Optionable

Receive HARP News and Ratings via Email

Sign-up to receive the latest news and ratings for HARP and its competitors with MarketBeat's FREE daily newsletter.


Harpoon Therapeutics (NASDAQ:HARP) Frequently Asked Questions

What is Harpoon Therapeutics' stock symbol?

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics Inc (NASDAQ:HARP) issued its earnings results on Wednesday, November, 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.56) by $0.09. The firm earned $1.42 million during the quarter, compared to analyst estimates of $1.09 million. Harpoon Therapeutics had a negative net margin of 1,107.97% and a negative return on equity of 86.88%. View Harpoon Therapeutics' Earnings History.

When is Harpoon Therapeutics' next earnings date?

Harpoon Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Harpoon Therapeutics.

What price target have analysts set for HARP?

6 Wall Street analysts have issued 1-year target prices for Harpoon Therapeutics' stock. Their forecasts range from $23.00 to $26.00. On average, they expect Harpoon Therapeutics' share price to reach $24.40 in the next year. This suggests a possible upside of 23.3% from the stock's current price. View Analyst Price Targets for Harpoon Therapeutics.

What is the consensus analysts' recommendation for Harpoon Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Harpoon Therapeutics.

Has Harpoon Therapeutics been receiving favorable news coverage?

News stories about HARP stock have trended somewhat positive recently, according to InfoTrie. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Harpoon Therapeutics earned a daily sentiment score of 1.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the company's share price in the near future. View News Stories for Harpoon Therapeutics.

Are investors shorting Harpoon Therapeutics?

Harpoon Therapeutics saw a decrease in short interest in November. As of November 15th, there was short interest totalling 147,900 shares, a decrease of 22.7% from the October 31st total of 191,300 shares. Based on an average daily volume of 52,100 shares, the short-interest ratio is presently 2.8 days. Currently, 1.2% of the company's shares are sold short. View Harpoon Therapeutics' Current Options Chain.

Who are some of Harpoon Therapeutics' key competitors?

What other stocks do shareholders of Harpoon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Alector (ALEC), Editas Medicine (EDIT), NVIDIA (NVDA), Universal Display (OLED), Advanced Micro Devices (AMD), Activision Blizzard (ATVI), Cisco Systems (CSCO), Docusign (DOCU), Intel (INTC) and Kaleido Biosciences (KLDO).

Who are Harpoon Therapeutics' key executives?

Harpoon Therapeutics' management team includes the folowing people:
  • Dr. Luke B. Evnin, Chairman (Age 56)
  • Dr. Gerald McMahon, Pres, CEO & Director (Age 64)
  • Dr. Holger Wesche Ph.D., Chief Scientific Officer (Age 51)
  • Dr. Natalie R. Sacks, Chief Medical Offer (Age 54)
  • Ms. Georgia L. Erbez, Chief Financial Officer (Age 52)

When did Harpoon Therapeutics IPO?

(HARP) raised $76 million in an initial public offering on Friday, February 8th 2019. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Leerink Partners acted as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

Who are Harpoon Therapeutics' major shareholders?

Harpoon Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State Street Corp (0.44%), California State Teachers Retirement System (0.05%), Barclays PLC (0.03%) and Tower Research Capital LLC TRC (0.01%). Company insiders that own Harpoon Therapeutics stock include Bioscience Plc Arix, Gerald Phd Mcmahon, Luke Evnin and Natalie Sacks. View Institutional Ownership Trends for Harpoon Therapeutics.

Which major investors are buying Harpoon Therapeutics stock?

HARP stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Barclays PLC, California State Teachers Retirement System and Tower Research Capital LLC TRC . Company insiders that have bought Harpoon Therapeutics stock in the last two years include Bioscience Plc Arix, Gerald Phd Mcmahon and Luke Evnin. View Insider Buying and Selling for Harpoon Therapeutics.

How do I buy shares of Harpoon Therapeutics?

Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Harpoon Therapeutics' stock price today?

One share of HARP stock can currently be purchased for approximately $19.80.

How big of a company is Harpoon Therapeutics?

Harpoon Therapeutics has a market capitalization of $487.71 million and generates $4.75 million in revenue each year. The company earns $-27,370,000.00 in net income (profit) each year or ($25.65) on an earnings per share basis. Harpoon Therapeutics employs 45 workers across the globe.View Additional Information About Harpoon Therapeutics.

What is Harpoon Therapeutics' official website?

The official website for Harpoon Therapeutics is http://www.harpoontx.com/.

How can I contact Harpoon Therapeutics?

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-7400 or via email at [email protected]


MarketBeat Community Rating for Harpoon Therapeutics (NASDAQ HARP)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  30 (Vote Outperform)
Underperform Votes:  44 (Vote Underperform)
Total Votes:  74
MarketBeat's community ratings are surveys of what our community members think about Harpoon Therapeutics and other stocks. Vote "Outperform" if you believe HARP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HARP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel